AU2001247951A1 - Novel cationic amphiphiles - Google Patents

Novel cationic amphiphiles

Info

Publication number
AU2001247951A1
AU2001247951A1 AU2001247951A AU4795101A AU2001247951A1 AU 2001247951 A1 AU2001247951 A1 AU 2001247951A1 AU 2001247951 A AU2001247951 A AU 2001247951A AU 4795101 A AU4795101 A AU 4795101A AU 2001247951 A1 AU2001247951 A1 AU 2001247951A1
Authority
AU
Australia
Prior art keywords
novel cationic
cationic amphiphiles
amphiphiles
novel
cationic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001247951A
Inventor
Thomas Fichert
Ulrich Massing
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roche Diagnostics GmbH
Roche Diagnostics Corp
Original Assignee
Roche Diagnostics GmbH
Roche Diagnostics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roche Diagnostics GmbH, Roche Diagnostics Corp filed Critical Roche Diagnostics GmbH
Publication of AU2001247951A1 publication Critical patent/AU2001247951A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
AU2001247951A 2000-02-07 2001-02-05 Novel cationic amphiphiles Abandoned AU2001247951A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18060000P 2000-02-07 2000-02-07
US60180600 2000-02-07
PCT/US2001/040020 WO2001057064A2 (en) 2000-02-07 2001-02-05 Cationic amphiphiles for use in nucleic acid transfection

Publications (1)

Publication Number Publication Date
AU2001247951A1 true AU2001247951A1 (en) 2001-08-14

Family

ID=22661057

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001247951A Abandoned AU2001247951A1 (en) 2000-02-07 2001-02-05 Novel cationic amphiphiles

Country Status (4)

Country Link
US (1) US20030229037A1 (en)
EP (1) EP1261620A2 (en)
AU (1) AU2001247951A1 (en)
WO (1) WO2001057064A2 (en)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7183263B2 (en) * 2002-07-17 2007-02-27 University Of Utah Research Foundation Linear polyethylenimine-sterol conjugates for gene delivery
US9228186B2 (en) 2002-11-14 2016-01-05 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
DE10303669A1 (en) * 2003-01-28 2004-07-29 Hans-Knöll-Institut für Naturstoff-Forschung e.V. New quaternary ammonioalkyl carbonate esters useful for treating bacterial and fungal infections and potentially useful for regulating cholesterol biosynthesis
EP1457483A1 (en) * 2003-03-11 2004-09-15 Ruhr-Universität Bochum Cationic lipids with serine backbone
AU2005222902B2 (en) 2004-03-12 2010-06-10 Alnylam Pharmaceuticals, Inc. iRNA agents targeting VEGF
EP1674081A1 (en) * 2004-12-23 2006-06-28 KTB Tumorforschungsgesellschaft mbH Preparation of lipid based nano-particles with a dual asymetric centrifuge
GB0502482D0 (en) * 2005-02-07 2005-03-16 Glaxo Group Ltd Novel compounds
CN103614375A (en) 2006-05-11 2014-03-05 阿尔尼拉姆医药品有限公司 Composition and method for inhibiting expression of PCSK9 gene
US8598333B2 (en) * 2006-05-26 2013-12-03 Alnylam Pharmaceuticals, Inc. SiRNA silencing of genes expressed in cancer
WO2008089771A1 (en) * 2007-01-24 2008-07-31 Syddansk Universitet Dna controlled assembly of lipid membranes
CA2713379A1 (en) * 2008-01-31 2009-11-05 Alnylam Pharmaceuticals, Inc. Optimized methods for delivery of dsrna targeting the pcsk9 gene
CA2716793A1 (en) * 2008-03-05 2009-09-11 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of eg5 and vegf genes
JP5529142B2 (en) 2008-09-25 2014-06-25 アルナイラム ファーマシューティカルズ， インコーポレイテッド Lipid formulation composition and method for inhibiting expression of serum amyloid A gene
AU2009303345B2 (en) * 2008-10-09 2015-08-20 Arbutus Biopharma Corporation Improved amino lipids and methods for the delivery of nucleic acids
US8168775B2 (en) 2008-10-20 2012-05-01 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of transthyretin
HUE037082T2 (en) * 2008-11-10 2018-08-28 Arbutus Biopharma Corp Novel lipids and compositions for the delivery of therapeutics
AU2009324534B2 (en) 2008-12-10 2015-07-30 Alnylam Pharmaceuticals, Inc. GNAQ targeted dsRNA compositions and methods for inhibiting expression
US20100267806A1 (en) * 2009-03-12 2010-10-21 David Bumcrot LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF Eg5 AND VEGF GENES
DK2440183T3 (en) * 2009-06-10 2018-10-01 Arbutus Biopharma Corp Improved lipid formulation
EA201270019A1 (en) * 2009-06-15 2012-06-29 Элнилэм Фармасьютикалз, Инк. BENTROVAL RNA INCLUDED IN LIPID COMPOSITION AND WHICH IS THE PCSK9 GENE
US9051567B2 (en) 2009-06-15 2015-06-09 Tekmira Pharmaceuticals Corporation Methods for increasing efficacy of lipid formulated siRNA
WO2011020023A2 (en) 2009-08-14 2011-02-17 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus
WO2011038031A1 (en) 2009-09-22 2011-03-31 Alnylam Pharmaceuticals, Inc. Dual targeting sirna agents
US9101643B2 (en) 2009-11-03 2015-08-11 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of transthyretin (TTR)
NZ605079A (en) * 2010-06-03 2015-08-28 Alnylam Pharmaceuticals Inc Biodegradable lipids for the delivery of active agents
WO2013016058A1 (en) * 2011-07-22 2013-01-31 Merck Sharp & Dohme Corp. Novel bis-nitrogen containing cationic lipids for oligonucleotide delivery
KR102263352B1 (en) 2011-11-18 2021-06-11 알닐람 파마슈티칼스 인코포레이티드 RNAi AGENTS, COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING TRANSTHYRETIN (TTR) ASSOCIATED DISEASES
ES2921724T1 (en) 2011-12-07 2022-08-31 Alnylam Pharmaceuticals Inc Biodegradable lipids for the administration of active agents
US20140045913A1 (en) * 2011-12-12 2014-02-13 Kyowa Hakko Kirin Co., Ltd. Lipid nano particles comprising combination of cationic lipid
FR3001217B1 (en) * 2013-01-21 2015-08-14 Biocellchallenge AMPHIPHILIC DERIVATIVES OF TRIAZAMACROCYCLE COMPOUNDS, PRODUCTS AND COMPOSITIONS COMPRISING SAME, PROCESSES FOR THEIR SYNTHESIS AND USES THEREOF
US9820942B2 (en) * 2013-03-06 2017-11-21 Biomics Biotechnologies Co., Ltd. Lipidosome preparation, preparation method and application thereof
PL3185957T3 (en) 2014-08-29 2022-11-14 Alnylam Pharmaceuticals, Inc. Patisiran for use in treating transthyretin mediated amyloidosis
LT3329002T (en) 2015-07-31 2021-01-11 Alnylam Pharmaceuticals, Inc. Transthyretin (ttr) irna compositions and methods of use thereof for treating or preventing ttr-associated diseases
MA50267A (en) 2017-09-19 2020-07-29 Alnylam Pharmaceuticals Inc COMPOSITIONS AND METHODS OF TREATMENT OF TRANSTHYRETIN-MEDIA AMYLOSIS (TTR)
WO2023014677A1 (en) 2021-08-03 2023-02-09 Alnylam Pharmaceuticals, Inc. Transthyretin (ttr) irna compositions and methods of use thereof
WO2023141562A1 (en) * 2022-01-20 2023-07-27 Emory University Phosphate membrane nanodiscs conjugated to therapeutic agents and medical uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2889318A (en) * 1957-02-18 1959-06-02 Searle & Co Sterol aminoalkyl carbonates
JP2604268B2 (en) * 1990-04-09 1997-04-30 富士写真フイルム株式会社 Liposomes and thin films using peptide derivative amphiphilic compounds, intermediates thereof, and peptide derivative amphiphilic compounds
DE4013632A1 (en) * 1990-04-27 1991-10-31 Max Planck Gesellschaft LIPOSOMES WITH POSITIVE EXCESS CHARGE
US5283185A (en) * 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
ES2123307T3 (en) * 1995-02-24 1999-01-01 Kao Corp QUATERNARY AMMONIUM SALT, METHOD FOR THE MANUFACTURE OF THE SAME AND ITS USE AS A SOFTENING COMPOSITION.
JPH0921068A (en) * 1995-06-30 1997-01-21 Kao Corp Liquid softening finish composition
WO1998010649A1 (en) * 1996-09-13 1998-03-19 University Technology Corporation Biocompatible cationic detergents and uses therefor
FR2759382A1 (en) * 1997-02-10 1998-08-14 Transgene Sa NOVEL COMPOUNDS AND COMPOSITIONS CONTAINING THEM FOR USE IN TRANSFERRING AT LEAST ONE THERAPEUTICALLY ACTIVE SUBSTANCE, IN PARTICULAR A POLYNUCLEOTIDE, INTO A TARGET CELL AND USE IN GENE THERAPY

Also Published As

Publication number Publication date
WO2001057064A3 (en) 2002-06-20
EP1261620A2 (en) 2002-12-04
US20030229037A1 (en) 2003-12-11
WO2001057064A2 (en) 2001-08-09

Similar Documents

Publication Publication Date Title
AU2001247951A1 (en) Novel cationic amphiphiles
AU2001262847A1 (en) Language-understanding
AU2001292739A1 (en) 1-oxorapamycins
AU2000267458A1 (en) Hypercomputer
AU2001254546A1 (en) Aminopiperidines
AU2001239310A1 (en) Decahydro-isoquinolines
AU2001265089A1 (en) Rc-timer scheme
AU2001220246A1 (en) Neckphone
AU2002211620A1 (en) Autoanastomosis
AU2001258349A1 (en) Bisacylguanidine
AU2001296577A1 (en) Chlorophyllases
AU2001279754A1 (en) Indoloquinazolinones
AU2001281965A1 (en) Novel 6-phenylphenanthridines
AU2002211128A1 (en) Step-bike
AU2001285886A1 (en) 2-guanidino-4-aryl-quinazoline
AU2001290931A1 (en) Ski-snowboard
AU2001293852A1 (en) Sulfonylguanidine
AU2001258924A1 (en) Microsatellite-aflp
AU2002226346A1 (en) 2-aryl-5-trifluoromethylpyridines
AU2001281921A1 (en) Bdellosomes
AU2001246864A1 (en) Hypotensors
AU2001291876A1 (en) Triazolo-epothilones
AU2002214354A1 (en) Neck-phone
AU2001260192A1 (en) Glycinamides
AU2001226668A1 (en) Crankshaft-starter-generator